ES2168383T3 - Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor. - Google Patents

Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.

Info

Publication number
ES2168383T3
ES2168383T3 ES95932217T ES95932217T ES2168383T3 ES 2168383 T3 ES2168383 T3 ES 2168383T3 ES 95932217 T ES95932217 T ES 95932217T ES 95932217 T ES95932217 T ES 95932217T ES 2168383 T3 ES2168383 T3 ES 2168383T3
Authority
ES
Spain
Prior art keywords
group
substituted
carboxyl
mono
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932217T
Other languages
English (en)
Inventor
Jun-Ichi Shishikura
Hiroshi Inami
Shuichi Sakamoto
Shin-Ichi Tsukamoto
Masao Sasamata
Masamichi Okada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2168383T3 publication Critical patent/ES2168383T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION DESCRIBE UN DERIVADO 1,2,3,4-QUINOXALINADIONA, REPRESENTADO POR LA FORMULA SIGUIENTE (I), O UNA SAL DEL MISMO, ASI COMO UN RECEPTOR DE GLICINA TIPO NMDA Y/O UN ANTAGONISTA DEL RECEPTOR AMPA, O UN INHIBIDOR DE LA NEUROTOXICIDAD DEL ACIDO CAINICO, QUE CONTIENE DICHO DERIVADO O SU SAL. ADEMAS, SE PRESENTA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO Y UN TRANSPORTADOR FARMACEUTICAMENTE ACEPTABLE. (I) DONDE LOS SIMBOLOS QUE APARECEN EN LA FORMULA ANTERIOR, TIENEN LOS SIGNIFICADOS SIGUIENTES, RESPECTIVAMENTE: X: N, CH, R: UN GRUPO IMIDAZOLILO, O UN GRUPO DIALQUILAMINO INFERIOR, R{SUP,1}: (1) UN ATOMO DE HALOGENO, UN GRUPO NITRO, CARBOXILO, AMINO, MONOO DIALQUILAMINO INFERIOR, ALCANOILO INFERIOR, ALQUILSUFINILO INFERIOR, ALQUILSULFONILO INFERIOR, O CARBAMOILO, (2) UN GRUPO ALQUILO INFERIOR O ALCOXILO INFERIOR, QUE PUEDE ESTAR SUSTITUIDO CON UN ATOMO DE HALOGENO, CON UN GRUPO CARBOXILO, O CON UN GRUPO ARILO, (3) UN GRUPO FENOXILO, QUE PUEDE ESTAR SUSTITUIDO CON UN GRUPOALCOXICARBONILO INFERIOR O CON UN GRUPO CARBOXILO, R{SUP,2}: UN GRUPO HIDROXILO, ALCOXILO INFERIOR, AMINO O MONOO DIALQUILAMINO INFERIOR, A: UN GRUPO ALQUILENO INFERIOR, QUE PUEDE ESTAR SUSTITUIDO, O UN GRUPO REPRESENTADO POR LA FORMULA -O-B-, Y B: UN GRUPO ALQUILENO INFERIOR, CON LA CONDICION DE QUE, SE EXCLUYE EL CASO EN EL QUE R REPRESENTA UN GRUPO IMIDAZOLILO, R{SUP,1} REPRESENTA UN GRUPO CIANO, A REPRESENTA UN GRUPO ETILENO, Y R{SUP,2} REPRESENTA UN GRUPO HIDROXILO.
ES95932217T 1994-09-27 1995-09-25 Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor. Expired - Lifetime ES2168383T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23190894 1994-09-27
JP5948295 1995-03-17

Publications (1)

Publication Number Publication Date
ES2168383T3 true ES2168383T3 (es) 2002-06-16

Family

ID=26400527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932217T Expired - Lifetime ES2168383T3 (es) 1994-09-27 1995-09-25 Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.

Country Status (16)

Country Link
US (1) US6096743A (es)
EP (1) EP0784054B1 (es)
KR (1) KR100392151B1 (es)
CN (1) CN1067387C (es)
AT (1) ATE209644T1 (es)
CA (1) CA2199468C (es)
DE (1) DE69524246T2 (es)
DK (1) DK0784054T3 (es)
ES (1) ES2168383T3 (es)
HU (1) HU223945B1 (es)
MX (1) MX9702244A (es)
PL (1) PL181532B1 (es)
PT (1) PT784054E (es)
RU (1) RU2149873C1 (es)
UA (1) UA44283C2 (es)
WO (1) WO1996010023A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057304A (en) * 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DE19519979A1 (de) * 1995-05-24 1996-11-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
ATE255089T1 (de) * 1997-03-14 2003-12-15 Meiji Seika Kaisha Physiologisch aktive substanz pf1191 und verfahren zu ihrer herstellung
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
EP1097927B1 (en) 1998-06-01 2006-07-19 Shionogi & Co., Ltd. Cyanoiminoquinoxaline derivatives
US6825192B1 (en) 1999-02-15 2004-11-30 Eisai Co., Ltd. Heterodiazinone derivatives
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6709667B1 (en) 1999-08-23 2004-03-23 Conceptus, Inc. Deployment actuation system for intrafallopian contraception
CN1298704C (zh) * 2000-01-24 2007-02-07 神经研究公司 具有神经营养活性的靛红衍生物
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
EP2322644A1 (en) * 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
MXPA04009496A (es) 2002-03-29 2005-01-25 Yamanouchi Pharma Co Ltd Remedio para glioblastoma.
JPWO2003087091A1 (ja) * 2002-04-17 2005-08-18 アステラス製薬株式会社 キノキサリンジオン誘導体無水物の新規結晶
JPWO2004002488A1 (ja) * 2002-06-28 2005-10-27 アステラス製薬株式会社 脳出血治療剤
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
PT1871368E (pt) * 2005-04-04 2011-08-30 Eisai R&D Man Co Ltd COMPOSTOS DE DIHIDROPIRIDINA PARA DOENÇAS NEURODEGENERATIVAS E DEMjNCIA
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
CA2687948A1 (en) * 2007-05-29 2008-12-04 Mamoru Matsuda Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein andhas glucocorticoid receptor-binding activity
EP2170334B1 (en) * 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
EP4403184A1 (en) 2021-09-15 2024-07-24 University of The Ryukyus Pharmaceutical composition for use in treating cognitive decline, excess weight, or obesity
WO2023042888A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556393B1 (en) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH07165756A (ja) * 1993-12-14 1995-06-27 Yamanouchi Pharmaceut Co Ltd ヒドロキシキノキサリンジオン誘導体
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Also Published As

Publication number Publication date
EP0784054A1 (en) 1997-07-16
KR970706274A (ko) 1997-11-03
KR100392151B1 (ko) 2003-11-20
ATE209644T1 (de) 2001-12-15
CA2199468C (en) 2006-06-06
DE69524246D1 (de) 2002-01-10
UA44283C2 (uk) 2002-02-15
PL320059A1 (en) 1997-09-01
AU684392B2 (en) 1997-12-11
US6096743A (en) 2000-08-01
EP0784054A4 (en) 1998-01-07
MX9702244A (es) 1997-06-28
PL181532B1 (pl) 2001-08-31
RU2149873C1 (ru) 2000-05-27
PT784054E (pt) 2002-05-31
DE69524246T2 (de) 2002-06-27
DK0784054T3 (da) 2002-03-25
AU3533795A (en) 1996-04-19
HUT77442A (hu) 1998-04-28
CN1168670A (zh) 1997-12-24
WO1996010023A1 (fr) 1996-04-04
CA2199468A1 (en) 1996-04-04
HU223945B1 (hu) 2005-03-29
EP0784054B1 (en) 2001-11-28
CN1067387C (zh) 2001-06-20

Similar Documents

Publication Publication Date Title
ES2168383T3 (es) Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.
DE69428476D1 (de) Heterocyclische Verbindungen als Bradykinin Antagonisten
TW221434B (es)
CA2311742A1 (en) 6-amino-9-benzyl-8-hydroxypurine derivatives
RU2003115429A (ru) Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
ATE448226T1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
DE69418704D1 (de) Anthranilsäure derivate
IL101785A0 (en) Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
RU97104870A (ru) 1,2,3,4-тетрагидрохиноксалиндионовое производное
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
ES2091489T3 (es) Derivados de imidazol y composiciones farmaceuticas que los contienen.
DE69021855D1 (de) Quinazolinderivate und ihre Herstellung.
NO20053302D0 (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
DE69000224D1 (en) Thioformamidderivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 784054

Country of ref document: ES